Anzeige
Mehr »
Login
Dienstag, 21.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Die Wachstumsgeschichte: Analysten sehen kurzfristige +37 %-Chance bei diesem europäischen Marktführer
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P7ZZ | ISIN: CA36118A1003 | Ticker-Symbol:
NASDAQ
21.05.24
20:30 Uhr
21,520 US-Dollar
-0,030
-0,14 %
1-Jahres-Chart
FUSION PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
FUSION PHARMACEUTICALS INC 5-Tage-Chart

Aktuelle News zur FUSION PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
10.05.Fusion Pharmaceuticals Inc. - 8-K, Current Report-
09.05.Fusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer1
07.05.Fusion Pharmaceuticals Inc. - 10-Q, Quarterly Report1
07.05.Fusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical Program Updates62Presented interim data from TATCIST trial of FPI-2265 in mCRPC at the 2024 American Association for Cancer Research (AACR) Annual Meeting Signed definitive agreement to be acquired by AstraZeneca for...
► Artikel lesen
02.05.Fusion Pharmaceuticals Inc. - 8-K, Current Report1
26.04.Fusion Pharmaceuticals (FUSN) to Report Q1 Earnings: Here's What to Expect1
25.04.Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order372HAMILTON, ON and BOSTON, April 25, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjucates (RCs)...
► Artikel lesen
23.04.Fusion Pharmaceuticals Inc. - 8-K, Current Report1
12.04.Fusion Pharmaceuticals Inc. - 10-K/A, Annual Report2
09.04.Fusion Pharmaceuticals Inc. - 8-K, Current Report2
09.04.Fusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 202470Preliminary data demonstrate FPI-2265 is active in heavily pretreated patients with progressive metastatic castration-resistant prostate cancer (mCRPC), including those who received prior lutetium-based...
► Artikel lesen
25.03.AstraZeneca to Acquire Fusion Pharmaceuticals, for Up To $2.4 Billion5
22.03.Pharma Stock Roundup: AZN to Buy FUSN, PFE to Sell Stake in HLN & Other Updates4
20.03.Recap: Fusion Pharmaceuticals Q4 Earnings5
20.03.Fusion Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary2
20.03.Fusion Pharmaceuticals GAAP EPS of -$0.39 misses by $0.061
20.03.Fusion Pharmaceuticals Inc. - S-8, Securities to be offered to employees in employee benefit plans1
20.03.Fusion Pharmaceuticals Inc. - 10-K, Annual Report1
20.03.Fusion Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Clinical Program Updates62Company recently announced definitive agreement to be acquired by AstraZeneca FPI-2265 Phase 2/3 registrational program for patients with metastatic castration-resistant prostate cancer (mCRPC) expected...
► Artikel lesen
20.03.AstraZeneca Acquiring Fusion Pharmaceuticals In $2 Billion Deal7
Seite:  Weiter >>
83 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1